USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
PLX PHARMA, INC.
Address:
8285 EL RIO
HOUSTON, TX
Phone:
N/A
URL:
N/A
EIN:
114185761
DUNS:
140243572
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $491,536.00 3
SBIR Phase II $2,594,097.00 3
STTR Phase I $147,318.00 1
STTR Phase II $1,533,011.00 1

Award List:

PC-NSAIDs: Gastrointestinal-safe and potent anti-inflammatory drugs

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$69,997.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Upendra Marathi, Senior Vice President
Abstract:
Contrasting in vitro and in vivo systems will be used to evaluate the anti-inflammatory/analgesic activity and side-effects of a family of phosphatidylcholine (PC) - associated NSAIDs. Previous studies indicate that PC-NSAIDs have equivalent and/or enhanced therapeutic activity while GI… More

PC-NSAIDs: Gastrointestinal-safe and potent anti-inflammatory drugs

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$729,991.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Upendra K. Marathi, Senior Vice President
Abstract:
We have developed a novel class of phosphatidylcholine (PC)-associated nonsteroidal antiinflammatory drugs (NSAIDs) to treat inflammation and pain with reduced GI side-effects. In Phase I studies using a number of in vitro systems monitoring the activity and threshold of nociceptive fibers under… More

GI-Safer Naproxen Formulation RandD for the Treatment of Osteoarthritis and Relat

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$263,605.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): ABSTRACT: This application is a Phase I/Phase II Fast-Track SBIR application. Osteoarthritis (OA), the clinical syndrome of joint pain and dysfunction caused by joint degeneration, affects more people than any other joi nt disease. There are no consistently… More

GI-Safer Naproxen Formulation RandD for the Treatment of Osteoarthritis and Related

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$745,708.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): ABSTRACT: This application is a Phase I/Phase II Fast-Track SBIR application. Osteoarthritis (OA), the clinical syndrome of joint pain and dysfunction caused by joint degeneration, affects more people than any other joi nt disease. There are no consistently… More

GI-Safer Formulation of Indomethacin for use in Preterm Neonates

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$157,934.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This application is a Phase I SBIR grant application. One of the major causes of morbidity and mortality of low birth weight neonates relates to injury, inflammation, perforation and obstruction of the lower GI tract, w hich can be manifest in the related… More

GI-Safer Formulation of Indomethacin for use in Preterm Neonates

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$1,118,398.00
Agency:
HHS
Principal Investigator:
Upendra K. Marathi – 713-842-1249
Abstract:
DESCRIPTION (provided by applicant): This application is for a SBIR Phase II grant. One of the major causes of morbidity and mortality of low birth weight neonates relates to injury, inflammation, perforation and obstruction of the lower GI tract, which can be manifest in the related diseases… More

Aspirin-PC for Chemoprevention of Colorectal Cancer

Award Year / Program / Phase:
2013 / STTR / Phase I
Award Amount:
$147,318.00
Agency:
HHS
Principal Investigator:
Lenard M. Lichtenberger – 713-500-6318
Research Institution:
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Colorectal cancer is the third leading cause of cancer-related deaths in the U.S. Based on numerous epidemiological studies and recent prospective trials; the use of daily aspirin is associated with a significant reduction in colorectl cancer incidence, deaths… More